Present and future therapies of hepatitis B: From discovery to cure

T. Jake Liang, Timothy M. Block, Brian J. McMahon, Marc G. Ghany, Stephan Urban, Ju‐Tao Guo, Stephen Locarnini, Fabien Zoulim, Kyong‐Mi Chang, Anna S. Lok – 3 August 2015 – Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million people worldwide. While treatment for HBV has improved, HBV patients often require lifelong therapies and cure is still a challenging goal.

Chemokine (C‐X‐C motif) receptor 3–positive B cells link interleukin‐17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma

Rui‐Xian Liu, Yuan Wei, Qiu‐Hui Zeng, Ka‐Wo Chan, Xiao Xiao, Xiao‐Yu Zhao, Min‐Min Chen, Fang‐Zhu Ouyang, Dong‐Ping Chen, Limin Zheng, Xiang‐Ming Lao, Dong‐Ming Kuang – 1 August 2015 – B cells consistently represent abundant cellular components in tumors; however, direct evidence supporting a role for B cells in the immunopathogenesis of human cancers is lacking, as is specific knowledge of their trafficking mechanisms.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Jakob Paur, Lisa Nika, Christiane Maier, Alexander Moscu‐Gregor, Julia Kostka, Daniela Huber, Thomas Mohr, Petra Heffeter, Waltraud C. Schrottmaier, Sonja Kappel, Daniela Kandioler, Klaus Holzmann, Brigitte Marian, Walter Berger, Michael Grusch, Bettina Grasl‐Kraupp – 1 August 2015 – Fibroblast growth factor receptors (FGFRs) are frequently up‐regulated in subsets of hepatocellular carcinoma (HCC). Here, we provide mechanistic insight that FGFR3 splice variants IIIb and IIIc impact considerably on the malignant phenotype of HCC cells.

Subscribe to